Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gossamer Bio ( (GOSS) ) has issued an announcement.
On February 23, 2026, Gossamer Bio reported topline Phase 3 PROSERA data showing that seralutinib did not meet the prespecified statistical threshold on its primary endpoint of six‑minute walk distance at Week 24 in the overall pulmonary arterial hypertension population, despite a nominally significant 13.3‑meter placebo‑adjusted gain. All four key secondary endpoints numerically favored seralutinib, including meaningful reductions in NT‑proBNP and trends toward better clinical improvement and risk score reduction, while safety was generally acceptable with more cough and higher liver enzyme elevations than placebo.
The trial revealed a notably stronger treatment effect in prespecified intermediate‑ and high‑risk patients, who achieved a 20‑meter placebo‑adjusted improvement in walk distance and robust biomarker and risk-score benefits, as well as a 37‑meter gain in connective tissue disease–associated PAH, suggesting differentiated value in these harder‑to‑treat segments. Operationally, Gossamer plans to pause enrollment in its SERANATA study to reassess development strategy and regional placebo effects, and will meet with U.S. regulators to determine whether these subgroup and secondary endpoint signals can support a viable path forward for seralutinib in a crowded PAH add‑on market.
The most recent analyst rating on (GOSS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Gossamer Bio stock, see the GOSS Stock Forecast page.
Spark’s Take on GOSS Stock
According to Spark, TipRanks’ AI Analyst, GOSS is a Neutral.
The score is primarily held down by weak financial performance: large operating losses, significant cash burn, and negative equity alongside meaningful debt. Technicals are mixed but somewhat supportive longer-term due to price holding above key longer moving averages, while valuation remains constrained by ongoing losses and lack of dividend support.
To see Spark’s full report on GOSS stock, click here.
More about Gossamer Bio
Gossamer Bio, Inc. is a biopharmaceutical company focused on developing innovative therapies for pulmonary arterial hypertension and related serious diseases. Its lead investigational product, seralutinib, is an inhaled tyrosine kinase inhibitor targeting PDGFR, CSF1R and c-KIT, delivered via dry powder inhalation to patients already receiving background PAH therapies.
The company operates in a highly competitive cardiopulmonary drug development market, where differentiation often hinges on efficacy in harder-to-treat subgroups and safety versus existing add-on treatments. By targeting high-risk PAH and connective tissue disease–associated PAH populations, Gossamer is positioning seralutinib as a potential add-on option in complex, multi-drug regimens.
Average Trading Volume: 4,682,385
Technical Sentiment Signal: Sell
Current Market Cap: $502.3M
For a thorough assessment of GOSS stock, go to TipRanks’ Stock Analysis page.